‘Embarrassing About-Face’: FDA’s Aduhelm Labeling Change Does Little To Improve Frustration Over Alzheimer’s Approval

 
• By Sarah Karlin-Smith
narrow hiking path
Change to Aduhelm label may narrow patient population for Alzherimer’s treatment. • Source: Alamy

More from US FDA

More from Agency Leadership